Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 8/20 | 0.51 |
| ▸ | P2RY2 | P41231 | 5/20 | 0.51 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.51 |
| ▸ | IARS1 | P41252 | 1/20 | 0.48 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.45 |
| ▸ | NT5E | P21589 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.45 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22387094 | 1.00 | P2RY6 (0.51) | P2RY6P2RY2P2RY4IARS1P2RY14 | |
| SCHEMBL23762553 | 1.00 | P2RY6 (0.51) | P2RY6P2RY2P2RY4IARS1P2RY14 | |
| SCHEMBL22387092 | 0.92 | P2RY6 (0.52) | P2RY6P2RY2P2RY4P2RY14NT5E | |
| SCHEMBL22387158 | 0.92 | P2RY6 (0.55) | P2RY6P2RY2P2RY4P2RY14NT5E | |
| SCHEMBL23762552 | 0.92 | P2RY6 (0.52) | P2RY6P2RY2P2RY4P2RY14NT5E | |
| SCHEMBL21345106 | 0.92 | P2RY6 (0.52) | P2RY6P2RY2P2RY4P2RY14NT5E | |
| SCHEMBL22387192 | 0.92 | P2RY6 (0.55) | P2RY6P2RY2P2RY4P2RY14NT5E | |
| SCHEMBL17165637 | 0.92 | P2RY6 (0.47) | P2RY6P2RY2P2RY4IARS1P2RY14 | |
| SCHEMBL17165639 | 0.92 | P2RY6 (0.47) | P2RY6P2RY2P2RY4IARS1P2RY14 | |
| Hydrochloric Acid SCHEMBL31201267 | 0.91 | P2RY6 (0.52) | P2RY6P2RY2P2RY4P2RY14NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11331331-B2 | N4-hydroxycytidine and derivatives and anti-viral uses related thereto | EMORY UNIVERSITY (US) | 2022-05-17 | — | — | US | disclosed |
| US-20220016153-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-01-20 | — | — | US | disclosed |
| US-11197882-B2 | — | — | 2021-12-14 | — | — | US | disclosed |
| US-11147826-B2 | — | — | 2021-10-19 | — | — | US | disclosed |
| US-20210252033-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-08-19 | — | — | US | disclosed |
| US-20200276219-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11331331-B2 | N4-hydroxycytidine and derivatives and anti-viral uses related thereto | ENTPD1, NME2, NME1 | P2RY6 380/4885P2RY2 843/4885P2RY4 232/4885 |
| US-11147826-B2 | — | SNRPE, NME2, NME1 | P2RY6 398/4885P2RY2 508/4885P2RY4 317/4885 |
| US-20220016153-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | ENTPD1, NME2, NME1 | P2RY6 380/4885P2RY2 843/4885P2RY4 232/4885 |
| US-20210252033-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | TYMP, MTAP, DCTD | P2RY6 694/4885P2RY2 1502/4885P2RY4 608/4885 |
| US-20200276219-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | ENTPD1, NME2, NME1 | P2RY6 380/4885P2RY2 843/4885P2RY4 232/4885 |
| US-11197882-B2 | — | SNRPE, NME2, NME1 | P2RY6 398/4885P2RY2 508/4885P2RY4 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.